CureVac

DGAP-News: CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry

Retrieved on: 
Monday, January 17, 2022 - 12:04pm

Further development of CureVac's unique mRNA technology platform will be led by Dr. Igor Splawski, Chief Scientific Officer of CureVac, and spearheaded by Dr. Patrick Baumhof, Senior Vice President Technology, who has a 15-year scientific tenure with the company.

Key Points: 
  • Further development of CureVac's unique mRNA technology platform will be led by Dr. Igor Splawski, Chief Scientific Officer of CureVac, and spearheaded by Dr. Patrick Baumhof, Senior Vice President Technology, who has a 15-year scientific tenure with the company.
  • "Mariola's dedication and expertise helped to build CureVac and fundamentally contributed to the advancement of mRNA technology as a whole."
  • "Mariola's groundbreaking work and innovations in mRNA technology have strongly contributed to CureVac becoming the world's pioneering company to harness mRNA for medical purposes," added Dr. Franz-Werner Haas, Chief Executive Officer of CureVac.
  • Mariola Fotin-Mleczek joined CureVac in May 2006 and became a member of the management board in 2013, first as Chief Scientific Officer and as Chief Technology Officer in 2018.

DGAP-News: dievini and The Federal Republic of Germany amend shareholders' agreement regarding investments in CureVac N.V.

Retrieved on: 
Thursday, January 13, 2022 - 10:08pm

DGAP-News: dievini Hopp BioTech holding GmbH & Co. KG

Key Points: 
  • DGAP-News: dievini Hopp BioTech holding GmbH & Co. KG
    dievini and The Federal Republic of Germany amend shareholders' agreement regarding investments in CureVac N.V.
  • dievini and The Federal Republic of Germany amend shareholders' agreement regarding investments in CureVac N.V.
    WALLDORF / BERLIN , Germany - 13 January 2022 - Today dievini and the Federal Republic of Germany announced the signing of a supplement to the shareholders' agreement between Kreditanstalt fr Wiederaufbau (KfW) and the investment company dievini Hopp BioTech holding GmbH & Co. KG (dievini), DH-LT-Investments GmbH, and Dietmar Hopp related to their common shares in CureVac N.V. (CureVac) (Nasdaq: CVAC).
  • In due course and solely to finance the restructuring (including tax obligations for involved parties), dievini intends to sell CureVac common shares.
  • Apart from this, dievini, Dietmar Hopp and his holding company, DH-LT-Investments, as well as the Federal Republic of Germany currently do not plan to sell CureVac common shares to third parties.

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Saturday, December 18, 2021 - 1:00am

The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individuals employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company.

Key Points: 
  • The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individuals employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company.
  • The options have an exercise price equal to $35.52 per share, the closing price of the Companys common stock as reported by Nasdaq on December 15, 2021.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries).

Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors

Retrieved on: 
Monday, December 13, 2021 - 1:00pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20211213005321/en/
    We are very pleased to welcome Dr. Jing Marantz, to the Arcturus Board, said Joseph Payne, President & CEO of Arcturus.
  • Jing will be an invaluable addition as Arcturus rapidly advances the development of its novel vaccines and therapeutic candidates.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • The Arcturus logo and other trademarks of Arcturus appearing in this announcement, including LUNAR and STARR, are the property of Arcturus.

Ondine Biomedical appoints new Board of Directors

Retrieved on: 
Tuesday, December 7, 2021 - 10:00am

Vancouver, Canada, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Canadian life sciences company, Ondine Biomedical, has appointed a new Board of Directors with considerable medtech and pharma expertise following its listing on the London AIM market.

Key Points: 
  • Vancouver, Canada, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Canadian life sciences company, Ondine Biomedical, has appointed a new Board of Directors with considerable medtech and pharma expertise following its listing on the London AIM market.
  • Carolyn Cross, Founder and CEO of Ondine, and Nicolas G. Loebel, PhD, President and Chief Technology Officer, will remain on the Board.
  • Ondine is at the forefront of development of photodisinfection-based therapies to address the large and growing need for solutions to a broad spectrum infections, including drug-resistant strains.
  • Steriwave has been deployed in Canadian hospitals for over ten years and has contributed to significant reductions in infection rates.

DGAP-News: CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine

Retrieved on: 
Monday, November 22, 2021 - 7:15pm

CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine

Key Points: 
  • CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine
    The issuer is solely responsible for the content of this announcement.
  • The newly published data features a direct comparison of CV2CoV with the licensed mRNA vaccine, Comirnaty(R) (Pfizer/BioNTech).
  • The data confirm how targeted optimizations of a non-chemically modified mRNA can significantly improve immune responses in a preclinical model, providing substantiated support for the unmodified mRNA technology approach.
  • This applies not only to the development of COVID-19 vaccines but to the mRNA technology field as a whole.

Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference

Retrieved on: 
Monday, November 22, 2021 - 1:00pm

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that members of the Companys management team will be participating in the Piper Sandlers 33rd Annual Virtual Healthcare Conference and investor meetings between November 30, 2021 and December 02, 2021.

Key Points: 
  • Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that members of the Companys management team will be participating in the Piper Sandlers 33rd Annual Virtual Healthcare Conference and investor meetings between November 30, 2021 and December 02, 2021.
  • A pre-recorded fireside chat will be available on-demand beginning on Monday, November 22 at 10:00 a.m.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries).

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, November 19, 2021 - 1:00am

The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individuals employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company.

Key Points: 
  • The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individuals employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company.
  • The options have an exercise price equal to $36.65 per share, the closing price of the Companys common stock as reported by Nasdaq on November 16, 2021.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries).

DGAP-News: CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response

Retrieved on: 
Wednesday, November 10, 2021 - 12:12pm

Extensive analysis of immune cell activation shows efficient stimulation of the immune system characterized by the induction of interferon alpha and interferon gamma signaling pathways.

Key Points: 
  • Extensive analysis of immune cell activation shows efficient stimulation of the immune system characterized by the induction of interferon alpha and interferon gamma signaling pathways.
  • Serial tumor biopsies from individual patients demonstrated increased infiltration of tumor-fighting T cells in the microenvironment of injected as well as non-injected tumors.
  • The data are being presented at the Society for Immunotherapy of Cancer (SITC) Conference, held in Washington, D.C., and virtually from November 10-14, 2021.
  • "The preliminary data from the Phase 1 dose escalation part of this study allow a much deeper understanding of the promising biologic effects of CV8102 observed in several patients," said Dr. Klaus Edvardsen, Chief Development Officer at CureVac.

Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021

Retrieved on: 
Monday, October 25, 2021 - 9:00pm

Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.

Key Points: 
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries).
  • In addition, please connect with us on Twitter and LinkedIn .
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20211025005719/en/